Specializes in biopharmaceutical products with focus in immunotherapy for the treatment of cancer

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Mycenax Biotech, Inc. engages in the research and development, manufacture, and sale of biopharmaceutical products. It offers new protein molecules and biosmilars. It provides contract development and manufacturing organization services including cell line development, process development, analytics and quality control, good manufacturing practice, aseptic fill and finish, and regulatory compliance services. The company was founded by Ching Ying Chen, Ching Chu Feng and Yi Hsu Huang on September 28, 2001 and is headquartered in Miaoli, Taiwan.

Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom.

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of patient-specific immunotherapies for the treatment of multiple sclerosis. The Company’s leading therapy candidate, Tcelna™, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. Opexa is located in The Woodlands, Texas north of Houston on one acre of forested land and houses its cGMP facility, research laboratories and corporate offices.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages.\nThe company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is an American company located in Wilmington, DE. The firm makes pharmaceuticals and drugs. E.I. du Pont de Nemours & Co., now a subsidiary of Corteva, Inc. acquired DuPont Merck Pharmaceutical Co. from Merck & Co., Inc. on July 01, 1998 for $2,600 million.

The Dutch Cancer Society (DCS; in Dutch: 'KWF Kankerbestrijding' ) is a Dutch Society committed to fight cancer by scientific research, education, patient support and fundraising in cooperation with volunteers, donors, patients, doctors and researchers. By this commitment, DCS targets less cancer, more cures and a higher quality of life for cancer patients. Its motto is, 'Everyone Deserves a Tomorrow' .

PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases. PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.